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Phase 1 and phase 2 gene therapy trials using intramuscular
(IM) administration of a recombinant adeno-associated virus
serotype 1 (rAAV1) for replacement of serum alpha-1 antitryp-
sin (AAT) deﬁciency have shown long-term (5-year) stable
transgene expression at approximately 2% to 3% of therapeutic
levels, arguing for the long-term viability of this approach to
gene replacement of secreted serum protein deﬁciencies. How-
ever, achieving these levels required 100 IM injections to deliver
135 mL of vector, and further dose escalation is limited by the
scalability of direct IM injection. To further advance the dose
escalation, we sought to bridge the rAAV-AAT clinical devel-
opment program to regional limb perfusion, comparing two
methods previously established for gene therapy, peripheral
venous limb perfusion (VLP) and an intra-arterial push and
dwell (IAPD) using rAAV1 and rAAV8 in a non-human pri-
mate (rhesus macaque) study. The rhesus AAT transgene was
used with a c-myc tag to enable quantiﬁcation of transgene
expression. 5 cohorts of animals were treated with rAAV1-
IM, rAAV1-VLP, rAAV1-IAPD, rAAV8-VLP, and rAAV8-
IAPD (n = 2–3), with a dose of 6  1012 vg/kg. All methods
were well tolerated clinically. Potency, as determined by serum
levels of AAT, of rAAV1 by the VLP method was twice that
observed with direct IM injection; 90 mg/mL with VLP versus
38 mg/mL with direct IM injection. There was an approximately
25-fold advantage in estimated vector genomes retained within
the muscle tissue with VLP and a 5-fold improvement in the ra-
tio of total vector genomes retained within muscle as compared
with liver. The other methods were intermediate in the potency
and retention of vector genomes. Examination of muscle
enzyme (CK) levels indicated rAAV1-VLP to be equally safe
as compared with IM injection, while the IAPDmethod showed
signiﬁcant CK elevation. Overall, rAAV1-VLP demonstrates
higher potency per vector genome injected and a greater total
vector retention within the muscle, as compared to IM injec-
tion, while enabling a much greater total dose to be delivered,
with equivalent safety. These data provide the basis for contin-
uation of the dose escalation of the rAAV1-AAT program in
patients and bode well for rAAV-VLP as a platform for replace-
ment of secreted proteins.
INTRODUCTION
Alpha-1 antitrypsin (AAT, or SERPINA1) is a highly abundant,
52-kDa serum protein. It is a multifunctional antiprotease, a member
of the serpin gene superfamily, which functions primarily to inhibit
the activity of neutrophil elastase (NE) and other neutrophil prote-
ases.1,2 Deﬁciency of AAT leads to progressive lung disease, due pri-
marily to the unopposed action of NE and other neutrophil products
on the extracellular matrix in the pulmonary interstitium. NE degra-
dation products are also pro-inﬂammatory, leading to enhanced
recruitment of neutrophils to the lung in response to infection or
other inﬂammatory stimuli, such as cigarette smoke. Thus, patients
with AAT deﬁciency suffer from progressive chronic obstructive pul-
monary disease with panacinar emphysema as the elastic recoil of the
lung is lost. There is a strong founder effect among Europeans with
AAT deﬁciency, with the E342K (PiZ) missense mutation accounting
for over 90% of disease-causing alleles. The allele frequency of PiZ is
1% to 2% in the European population.3 Current therapy consists
largely of protein replacement (augmentation therapy) and is avail-
able in the United States and some European countries, with the
approved dosing interval currently weekly by intravenous infusion,
leading to a substantial desire among patients for gene therapy to
be developed. Normal adult serum AAT levels range from 20 to
53 mM,2 and the threshold to prevent lung disease is 11 mM, making
it the most abundant serum protein for which gene therapy has been
attempted.
This work is a continuation of pre-clinical and clinical work to
develop a gene therapy for AAT deﬁciency. This work has focused
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on amuscle-based gene therapy platform using a recombinant adeno-
associated virus serotype 1 (rAAV1)-CB (chicken beta-actin pro-
moter with a CMV enhancer)-human alpha-one antitrypsin
(hAAT) vector to enable systemic secretion of the normal (wild-
type human alpha-one antitrypsin [PiM], M-AAT) version of the
AAT protein in AAT-deﬁcient patients. The endpoint for licensure
of rAAV1-CB-hAAT by the Food and Drug Administration (FDA)
is based on the serum level of AAT that has been shown to be protec-
tive from lung disease. This threshold is currently set at 11 mM of
M-AAT in the patient serum or plasma. The delivery of rAAV1-
CB-hAAT to the muscle of AAT-deﬁcient patients in previous trials
by our group has proven to be safe and has demonstrated a dose-
response relationship with a maximum patient serum level of approx-
imately 300 nM. The AAT serum levels have proven stable for 5 years
after a single set of 100 intramuscular (IM) injections with a vector
dose of 6 1012 vg/kg in a volume of 135 mL.4–6 Our previous patient
dose-escalation results suggest that further increases in vector dose
would result in elevations in serum M-AAT levels in an approxi-
mately linear fashion. However, increases in dose are limited by the
fact that the vector formulation cannot be concentrated signiﬁcantly
further and that an increase in the number of direct IM injections is
not tolerable to patients.
Based on these considerations, we have designed this as a bridging
study in rhesus macaques to compare direct IM injections to local
intravascular infusion. For this work, we utilized a c-myc-tagged rhe-
sus AAT gene so that the relative expression levels could be quantita-
tively compared. We chose to compare two intra-vascular delivery
protocols that have been previously published as efﬁcacious routes
of AAV administration to large animal models (Table S1). The ﬁrst
method involves intra-arterial delivery with a double balloon catheter
to the pelvic extremity, a method that has been successfully used in
non-human primates.7 Variations of the intra-arterial technique
have also been successfully used for AAV delivery in both non-human
primates and canine models (Table S1).8–13 We compared the intra-
arterial delivery to high-volume venous limb perfusion (VLP; also
called hydrodynamic intravenous delivery, or HID) into a tourni-
queted pelvic extremity.14–23 VLP has also been successfully used
for AAV delivery in both canids and non-human primates (Table
S1). The intra-arterial push and dwell (IAPD) and intravenous
(VLP) delivery methods were compared to direct IM injection using
an AAV rhesus AAT-c-myc vector (n = 3 per group for the rAAV1
IM group, rAAV1 VLP group, and rAAV8 VLP group; n = 2 for
the rAAV1 IAPD and rAAV8 IAPD groups) (Table 1). All animals
were given the same dose of AAV. The IAPD vector was given in a
total vector volume of 12 mL/kg, while the VLP vector was given in
a total volume of 50 mL/kg. We chose the AAV serotypes for this
study to bridge our current clinical program, in the case of AAV1,
and because of its utilization for both intravenous and intraarterial
limb perfusion previously in the case of AAV8 (Table S1). Only
AAV1 was given IM to directly compare the current AAV1 IM clin-
ical program to AAV1 delivered by limb perfusion.
VLP resulted in higher serum AAT levels when compared to IM
(AAV1)- and IAPD (AAV1 and AAV8)-dosed animals. IAPD using
AAV1 had comparable serum levels to those of animals dosed by IM
injection at day 60. These data support the use of VLP as a viable
delivery route for AAT gene therapy to skeletal muscle, allowing
comparable to improved expression and increased dosing scalability
due to the increase in the deliverable vector volume.
RESULTS
Limb Infusion Procedures
The limb perfusion methods used for this study are diagrammed in
Figure 1A. All animals tolerated both procedures well and recovered
without incidence. The IAPD procedure had a total procedure time of
around 4 h and required three surgical personnel, one anesthetist, and
two technical assistants to perform. The VLP procedure had a total
procedure time of around 1 h and required two technical assistants
and one anesthetist to perform. The increased procedural time with
the IAPD procedure resulted from the time to place the catheters sur-
gically and the time to conﬁrm catheter placement by ﬂuoroscopy.
Marked limb swelling was seen following the VLP procedure, but
this resolved completely within 12–24 h post-procedure and did
not alter the animal’s ability to use the limb normally, even immedi-
ately post-anesthesia (Figures 1B–1G).
Quantification of rhAAT-c-myc by Semi-Quantitative
Immunoblot of Serum
Taking advantage of the c-myc epitope tag, we developed a semiquan-
titative serum immunoblot method for the detection of the rhesus
AAT (rhAAT)-c-myc fusion protein, titrated against a series of
dilutions of a known standard. Immunoblots were performed using
serum collected at days 7, 14, 21, and 60 post-vector delivery (Fig-
ure 2A). Semiquantitative levels at each time point were then
Table 1. Rhesus Limb Infusion Experimental Design
Dose Group
Animal #
(Sex; NAb titer)
Test Article
(6  1012 vg/kg
for All Groups) Route Dosing Volume
IM-AAV1
RA1683 (F; 1:5) rAAV1-CB-
rhAATmyc
IM
0.5 mL per injection
(8 injections)RA1598 (M; 1:10)
IAPD-AAV1
RA1709 (F; 1:5) rAAV1-CB-
rhAATmyc
IAPD 12.5 mL/kg
RA1562 (M; 1:10)
IAPD-AAV8
RA1660 (F; 1:10) rAAV8-CB-
rhAATmyc
IAPD 12.5 mL/kg
RA1664 (F; 1:10)
VLP-AAV1
RA0770 (F; <1:5) rAAV1-CB-
rhAATmyc
VLP 50 mL/kg
RA1567 (M; 1:10)
VLP-AAV8
RA1676 (F; 1:10) rAAV8-CB-
rhAATmyc
VLP 50 mL/kg
RA1703 (F; 1:10)
All dosing was performed in the right hindlimb. Intramuscular dosing was performed as
a total of eight injections, four into the right quadriceps and four into the right gastroc-
nemius. NAb, neutralizing antibody titer (anti-AAV1 or anti-AAV8 titer listed depend-
ing on the vector delivered to that animal); IM, intramuscular; F, female; M, male; CB,
chicken beta-actin promoter with a CMV enhancer; rhAATmyc, rhesus alpha-1 anti-
trypsin gene with a c-myc tag; IAPD, intra-arterial push and dwell; VLP, venous limb
perfusion;
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determined by chemi-luminescence, and the value plotted in Fig-
ure 2B. VLP delivery of either rAAV1 or rAAV8 yielded an approx-
imately 2-fold increase in total serum transgene expression at day 60
when compared to day-60 rAAV1 IM-injected animals (Figures 2A
and 2B). Serum levels following IM injection of AAV1 were compa-
rable to those for animals dosed with AAV1 via the IAPD route at day
60. It should be noted that some animals in the AAV1 IM groups were
noted to have decreased serum levels of rhAAT-c-myc at day 60
compared to day 21. None of the differences were statistically
signiﬁcant.
Muscle Immunohistochemistry for AAT
AATmuscle expression was greatest around the injection sites for the
IM dose group. We saw widespread low-level expression in the IAPD
group for both the quadriceps and gastrocnemius (Figure 2C). We
observed increased expression in the gastrocnemius region for the
VLP group, with lower levels of positive myocytes in the quadriceps
(Figure 2C).
Real-Time qRT-PCR
Primers targeting the AAT-c-myc junction were utilized to identify
transgene RNA expression in the gastrocnemius muscle (from the
site of injection in the IM-dosed animals) and liver at day 60 post-deliv-
ery.Muscle expression was higher in the IM andVLP groups compared
to the IAPD groups (Figure 2D). In the liver, RNA levels were highest
in the VLP-AAV8 and IAPD-AAV8 groups (Figure 2D). All AAV1
dosing groups had similar liver expression. Muscle expression was
markedly higher than liver expression in all the AAV1 dosing groups.
Total Vector Genomes
In order to conﬁrm that the increased expression observed in the
rAAV1-VLP group was due to an increase in the total number of
vector genomes delivered to the lower extremity musculature, we per-
formed qPCR for rAAV vector genomes, normalized to the quantity
of genomic DNA (i.e., micrograms of gDNA) (Figure 3A; Table 2).
The volume of muscle transduced was estimated using the estimated
volume of the limb perfused by the vessel cannulated. In the case of
IM, the volume of injection was used as an estimate of the volume
of muscle tissue transduced, based on prior studies including
real-time ultrasound performed during deltoid muscle injections in
humans in a previous trial performed by our group.24 The number
of myoﬁber nuclei constituting that volume was then estimated
using the estimate of nuclear density previously published.25 This
comparison suggested a superiority of rAAV1-VLP delivery over
Figure 1. Representation of Limb Perfusion Routes and Images of the Dosed Limbs for Each Route of Delivery
(A) Graphical representation of venous limb perfusion (left) and intra-arterial push and dwell (right). (B–D) VLP dosed limb (B) at the start of delivery, (C) 5 min into the vector
infusion, and (D) after all vector had been infused but tourniquet had not been released. (E) Quadriceps dosing sight; note that intra-muscular (IM) injection sights are denoted
using a black marking pen. The animal’s body is to the left of the image and the knee is to the right. (F) Gastrocnemius dosing sight; note that IM injection sights are denoted
using a black marking pen. The animal’s knee is to the left of the image, and the foot is to the right. (G) Intra-arterial push and dwell (IAPD)-dosed limb at the end of infusion
before balloon catheters deflated (the image shows the inner aspect of the dosed limb).
www.moleculartherapy.org
Molecular Therapy: Methods & Clinical Development Vol. 13 June 2019 235
rAAV1-IM and other modes of muscle delivery. In fact, the number
of vector genome (vg) copies delivered to the muscle was estimated at
25 times greater with rAAV1-VLP than with rAAV1-IM (Table S2).
Next, we compared the total number of vgs retained within the mus-
cle (as described earlier) with the total number of vgs detected in the
liver, assuming that the liver of a rhesus macaque contains approxi-
mately 4.5 1010 nuclei, a value based on data fromMarcos and Cor-
reia-Gomes on the number of nuclei (from all cell types) per gram of
mammalian liver (4.5  108 nuclei per gram) and from Kim et al.,
indicating the average liver weight in a rhesus of approximately 100
g.26,27 These data were then used to calculate the ratio (as a percent-
age) of the total vgs detected within the muscle, as compared with the
total vgs detected within the liver, expressed as a percentage: (muscle
vg/liver vg)  100 (Table S2).
Interestingly, with direct IM injection of rAAV1-AAT, the total num-
ber of vg detected in the liver as a whole was estimated at 6.0  1010
vg, which is substantially greater than the amount retained within the
muscle, which was 1.37 108 vg.While rAAV1-VLP did result in a 3-
fold increase in total vg within the liver (up to 1.9 1011 vg), the pro-
portional estimated increase retained in the muscle was much greater
at over 25-fold (3.5  109 vg as compared with 1.37  108 vg). Esti-
mating the ratio of total vg in muscle as compared with liver, rAAV1-
IM showed only 0.22% of the abundance in liver, while rAAV1-VLP
showed muscle vg at 1.09% of the total detected in liver. This repre-
sents an estimated 5-fold increase in relative vg retention in muscle as
compared with liver.
Serum Chemistry and Complete Blood Count
We saw a moderate spike in serum creatine kinase, a marker of mus-
cle damage, 1 day after delivery and a mild spike 21 days after AAV1
IAPD delivery (Figure 4A). At day 1, all other groups had minimal to
no increase in serum creatine kinase. The IM group had a very mild
increase in CK in one animal at day 21. There was amoderate increase
in serum alanine aminotransferase (ALT) and aspartate aminotrans-
ferase (AST) at day 1 post-delivery in the IAPD AAV1 group as well
as a mild AST elevation at day 21 in that same group (Figures 4B and
4C). There were no other serum chemistry parameters or complete
blood counts that changed signiﬁcantly following vector dosing.
IFNg-ELISpot Response to AAV1 and AAV8 Capsids
The T cell response to both AAV1 and AAV8 capsids were monitored
by IFNg ELISpot assay (Table S3). Peripheral blood mononuclear
Figure 2. Serum AAT c-myc Expression, Muscle Immunohistochemistry for AAT, and RT-PCR
(A) Western blot gel image for all time points (please note that several AAV8 day-60 samples were missing). (B) Semi-quantitation of western blot (WB) data represented as
mean ± SEM. (C) Immunohistochemistry for AAT at day-60 representative sections for each dosing route for both AAV1 and AAV8. Muscle samples were collected for
immunohistochemistry (IHC) from the level of the IM injections in both the quadriceps and gastrocnemius. (D) RT-PCR data from day-60 muscle and liver tissue. The
gastrocnemius muscle samples were used for all groups. IM muscle samples were collected from the injection site. IM, intramuscular; IAPD, intra-arterial push and dwell;
VLP, venous limb perfusion.
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cells (PBMCs) were expanded for 6 days prior to the assay. Our results
showed that none of the animals injected IM had a positive response
prior to dosing and at day 60 post-delivery. One out of 3 animals
showed a mild positive response to the AAV1 capsid at day 60 post
VLP dosing (less than 350 spot-forming units [SFUs] per million of
cells) (Figure S1; Table S3). Regarding the animals injected with the
AAV8 vector, none of the animals injected via VLP had an IFNg-
positive response to the capsid prior to or post-dosing. One animal
injected via AAV8 IAPD showed a mild positive response at necropsy
(less than 200 SFUs per million of cells) (Figure S2; Table S3). Our
results suggest there is no or very limited systematic cellular immune
response to either AAV1 or AAV8 capsids after IM, VLP, and IAPD
vector administration.
DISCUSSION
The present study provides the ﬁrst direct comparison in non-human
primates of several previously published methods of delivery of rAAV
vector to limb musculature and effectively bridges the rAAV1-AAT
muscle delivery program from direct IM to VLP. All methods were
safe in terms of the overall clinical well-being of the animals. Expres-
sion levels similar to or higher than those for IM injection were
obtained using each of the limb perfusion methods. The rAAV1-
VLP method was the most efﬁcient, with a 25-fold increase in total
vg delivered to the muscle tissue and double the total vector transgene
expression. The rAAV1-VLP method did not result in a signiﬁcant
increase in muscle injury compared with rAAV1-IM, as measured
by serum CK levels and histology. The VLP method was also safer
than rAAV1-IAPD, which did demonstrate a short-term spike in
serum CK values 1 day after vector injection. Liver transaminase
Figure 3. Vector Distribution in the Muscle and
Estimated Total Vector Genomes in the Lower
Extremity
(A) Heatmap of distribution of vector genomes in themuscle
of both the dosed and undosed limbs 60 days post-de-
livery. IM, intramuscular; IAPD, intra-arterial push and dwell;
VLP, venous limb perfusion. n = 2 per group. (B) Total
vector genomes delivered to the targeted rhesus lower
extremity muscle, as estimated based on the volume of
muscle tissue perfused and the nuclear density of muscle
tissue.
elevations were also noted in the rAAV1-IAPD
group but not in the other dosing groups. The
rAAV1-VLP also preserved the preference of
delivery for muscle over liver, as demonstrated
by the fact that the total vector DNA amount
detected in the muscle was much greater in the
rAAV1-VLP group as compared with the
rAAV1-IM group (25-fold), while the increase
in liver vector DNA with VLP was only 3-fold.
Meanwhile, the same VLP method with rAAV8
resulted in a greater spread to liver than the
rAAV1-VLP group but did not mediate higher
expression. This suggests that the superiority of the rAAV1-VLP
for overall serum AAT expression is derived from muscle rather
than liver AAT expression. If the gene expression advantage had
been due to liver delivery, then the rAAV8-VLP group would have
been expected to express at a signiﬁcantly higher level.
Interestingly, while direct IM injection has been assumed to result in
muscle-restricted vector delivery, the proportion of total vector DNA
retained in muscle as compared with that in liver in the rAAV1-IM
group was only 0.22%. The same comparison with rAAV1-VLP
showed that total vg retention in muscle was 1.09% of that observed
in liver, about a 5-fold improvement in relative proportion. This is
consistent with the observation of greater total serumAAT expression
from the rAAV1-VLP group.
The safety proﬁle of rAAV1-VLP was excellent. The approach did not
result in signiﬁcant elevations in muscle or liver enzymes or in an
IFNg T cell response to the capsid. A positive IFNg T cell response
was observed in only 2 out of 13 animals. It is noteworthy that these
infrequent responses were mild and observed only after a cell expan-
sion of 6 days, and they were directed to both serotypes 1 and 8 after
VLP or IAPD administration, suggesting that the cellular immune
response is not systematic and not related to a given serotype or
method of delivery. Based on the results presented, we cannot rule
out a transgene immune response; this will be assessed, along with
cellular inﬁltrated into dosed muscle, in future experiments.
Overall, the rAAV1-VLP method appeared to be superior to rAAV1-
IM and other limb perfusion methods in the overall effectiveness of
www.moleculartherapy.org
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transgene expression and safety at matched doses of vg per kilogram.
We anticipate that a transition of the rAAV1-hAAT muscle-targeted
clinical gene therapy program from IM to VLP will allow for an
increased volume of vector to be delivered safely and effectively. Since
vector concentration has already been previously maximized, the
increase in volume allows a greater total dose of vector to be delivered
to the human subjects’ muscle while avoiding the increased risks of
arterial cannulation and the morbidity associated with a much large
number of IM injections. This bridging from IM to VLP will effec-
tively extend the work with the rAAV1-hAAT vector dose escalation
without any signiﬁcant increase in the risk to subjects from the
administration.
MATERIALS AND METHODS
Study Outline
Animals were selected based on serum neutralizing antibodies against
AAV1 or AAV8 as determined commercially by the University of
Massachusetts Gene Therapy Vector Core using an in vitro assay;
animals with a titer at or below 1:10 were selected. Five groups of
animals were administered rAAV1-CB-rhAATmyc or rAAV8-CB-
rhAATmyc by IM, IAPD, or VLP as assigned (Table 1) on study
day 0. The vector dose was 6 1012 vg/kg for all groups. After dosing,
animals were monitored by veterinary staff twice daily for 7 days for
pain, bleeding, suture loss, limping, or other signs. Detailed clinical
observations and body weight were recorded. At study day 60, ani-
mals were euthanized and subject to a complete necropsy, and blood
and tissues were collected for evaluation. All animal work was done
under the approval and supervision of the Lovelace Respiratory
Research Institute Animal Care and Use Committee.
Vector Design and Manufacturing
The vector was manufactured by Applied Genetic Technologies Corp
(AGTC) as previously described.4 Brieﬂy, the vector used for these
studies is an AAV2-inverted terminal repeat (AAV2-ITR) cassette,
cross-packaged into AAV1 capsids. The enhancer-promoter complex
is a commonly used constitutively active hybrid consisting of the
CMV-immediate early enhancer, the chicken beta-actin promoter,
and an intron from rabbit beta globin (CBA, alternatively known as
CAG). The transgene used for these studies is the rhAAT with an
in-frame fusion to the human-derived c-myc peptide fragment. Our
lab has used c-myc fusions of the AAT gene derived from the native
species for several previous preclinical studies including in baboons.28
The design enables one to quantify the transgene product expression
levels while minimizing immunologic responses against the AAT
gene.
The vector was packaged into AAV1 capsids using the recombinant
herpes simplex virus 1 (rHSV1) -system.29–33 In this system, two sepa-
rate rHSV1 stocks are used to infect baby hamster kidney (BHK) cells
used for upstream production. One was rHSV1-Rep2Cap1. The other
contained the AAV-CB-rhAATmyc expression cassette inserted into
an ICP27 deleted HSV-1 virus (d27.1). Cell lysis with Triton X-100
detergent was followed by Benzonase treatment to remove unpack-
aged DNA. The treated lysate was ﬁlter clariﬁed, concentrated, buffer
exchanged, and then column puriﬁed using CIM Q Monolith anion-
exchange chromatography followed by AVB Sepharose afﬁnity chro-
matography. The ﬁnal product was concentrated by tangential ﬂow,
exchanged to Ringer’s buffer, and passed through a 0.2-mm ﬁlter.
Vector Dosing
Test Article Preparation
The vector was administered in volumes dictated by the injection or
infusion procedure (Table 1). For each administration route, individ-
ual stock vials of vector were thawed and diluted on the day of use in
the appropriate concentration and volume to deliver the targeted
vector dose (6  1012 vg/kg). The vector was diluted with Lactated
Ringer’s Solution.
Intramuscular Injection
The animals were anesthetized with ketamine (10 mg/kg with
2–3 mg/kg bumps as needed) administered via IM injections. For
the IM dose group, rAAV1-CB-rhAATmyc vector was administered
as eight 0.5-mL injections (i.e., 4 mL of total dose volume), with the
concentration adjusted to achieve the desired total dose based on
the body weight of an animal. The injections were performed into
the quadriceps and gastrocnemius muscles in the right hindlimb,
Table 2. Tissue Vector Genomes
Tissues (Vector Genomes/mg gDNA)
Mean (SD)
Serotype-
Route
Right Upper
Quadriceps
(Dosed Limb)
Right Lower
Quadriceps
(Dosed Limb)
Right Calf
(Dosed Limb)
Right Inguinal
Lymph Node
(Dosed Limb)
Liver
Left Quadriceps
(Undosed Limb)
Left Calf
(Undosed
Limb)
Left Inguinal
Lymph Node
(Undosed Limb)
AAV1-IM 498,778 (281,500) 574,208 (562,329)
1,599,935
(1,115,968)
2,532,248
(1,319,764)
376,475 (387,624) 9,878 (11,388) 993 (1,118) 37,998 (30,675)
AAV1-IAPD 44,150 (37,218) 129,055 (127,706) 22,530 (18,723) 368,133 (111,128) 1,192,300 (284,074) 3,008 (2,120) 9,150 (5,185) 35,348 (25,648)
AAV8-IAPD 86,205 (91,689) 70,038 (25,065) 16,885 (8,792) 293,298 (103,261) 2,878,100 (1,665,077) 3,028 (2,099) 4,253 (2,648) 55,638 (47,087)
AAV1-VLP 10,188 (8,071) 9,045 (5,069) 783,635 (87,715) 2,213,788 (90,284) 1,961,980 (470,336) 13,040 (11,487) 9,025 (6,956) 92,483 (39,652)
AAV8-VLP 1,775 (526) 203,595 (121,972) 239,328 (84,476) 980,443 (19,295) 6,534,063 (5,428,745) 2,070 (319) 5,353 (4,253) 131,755 (–)
IM, intramuscular; IAPD, intra-arterial push and dwell; VLP, venous limb perfusion.
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with 4 injections in each muscle. The spacing between injections
depended on the size of the muscle but were 0.5 to 1 cm apart. The
injection sights were marked with a black marking pen for photog-
raphy of the injected limbs. Post-injection pain, if observed, was
managed with buprenorphine (0.01–0.03 mg/kg) administered via
IM injection. Thereafter, buprenorphine (0.01 to 0.03 mg/kg, IM in-
jection) was administered as needed, based on clinical observations.
Intravascular Limb Infusion
Pre-surgical Preparation and Anesthesia
Aseptic technique was used throughout the surgical procedure for the
IAPD and VLP delivery. For surgical procedures, animals were pre-
medicated with ketamine (10 mg/kg) administered intramuscularly.
Inhalant anesthesia (generally 1–4% isoﬂurane in oxygen for induc-
tion and 0.5–3% isoﬂurane in oxygen as needed for maintenance)
was administered via face mask to facilitate intubation. During the
operative procedure, anesthesia was maintained with 0.5–3% isoﬂur-
ane in oxygen administered via the endotracheal tube.
One or two venous catheters were placed in a peripheral vein in the
leg or arm (not the leg for the infusion). The catheters were used as
needed to inject heparin and protamine, to withdraw blood for assess-
ment of clotting time, and to provide Plasmalyte (5 mL/kg/h) during
the infusion procedure.
Intra-Arterial Push and Dwell
IAPD animals received the vector (rAAV1-CB-rhAATmyc or
rAAV8-CB-rhAATmyc) in a volume of 12.5 mL/kg of Lactated
Ringer’s Solution.
Buprenorphine (0.01 to 0.03 mg/kg, administered via IM injection)
was given preemptively at least 20 min prior to incising skin. The
Figure 4. Serum Creatine Kinase and Liver
Transaminase Levels following rAAV Rhesus AAT-c-
myc Delivery
(A) Serum levels of creatine kinase (CK), a marker of
myocyte damage. (B) Serum levels of alanine aminotrans-
ferase, a transaminase that increases in the serum
following hepatocellular damage. (C) Serum levels of
aspartate aminotransferase, a transaminase that increases
in the serum following hepatocellular damage. IM, intra-
muscular; IAPD, intra-arterial push and dwell; VLP, venous
limb perfusion; ALT, alanine aminotransferase; AST,
aspartate aminotransferase; AAV1 and AAV8, AAV capsid
types delivered. n = 2 per group.
surgical site was prepared according to standard
sterile procedure. After lidocaine (1 mg/kg) and
bupivacaine (1mg/kg) were administered by local
application at the incision site, an incision was
made in the lower anterior thigh of the right pel-
vic limb, and the superﬁcial femoral artery and
vein were dissected and isolated with silk suture.
Arterial and venous access was obtained with
sheath catheters. The catheters were inserted by the cut-down tech-
nique and then retrograde positioned into the upper femoral artery
and vein near the inguinal ligament. The arterial and venous balloon
catheters were then placed through their respective sheathes. The
stopcock on the venous catheter was turned to prevent venous
outﬂow. Correct placement of the catheters was checked by ﬂuoros-
copy, conﬁrming the presence of the arterial and venous balloons
above the level of the vascular branches leading to the quadricepsmus-
cle groups. Once the vein and artery were cannulated, heparin was
administered to achieve an activated clotting time of >350 s deter-
mined using an i-STAT clinical analyzer and an activated clotting
time (ACT) cartridge. The limb was elevated and wrapped tightly to
massage all venous blood from the limb, after which the catheter
balloons were inﬂated to prevent the vascular ﬂow of the femoral
vein and artery. The limb was then lowered and unwrapped. After a
pre-ﬂush with Lactated Ringer’s Solution (LRS) (5 mL/kg), the vector
(rAAV1-CB-rhAATmyc or rAAV8-CB-rhAATmyc) in a volume of
12.5 mL/kg was infused as quickly as possible though the arterial cath-
eter sheath port. The vector solution dwelled for 15 min, after which
repeat ﬂuoroscopy conﬁrmed that the balloons had remained inﬂated
through the entire dwell time. At that point, a post-ﬂush of 5mL/kg of
LRS was injected into the arterial catheter. After the infusion, the bal-
loons were deﬂated, and the catheters were removed. The effects of the
circulating heparin were reversed by the injection of protamine (0.5–
1 mg/100 United States Pharmacopeia [USP] heparin units adminis-
tered). Blood samples were obtained, and clotting times were checked.
When the clotting time had returned to near baseline value (±20 s), the
animal was recovered from anesthesia and returned to its home cage.
VLP
VLP-dosed animals received the vector (rAAV1-CB-rhAATmyc or
rAAV8-CB-rhAATmyc for group 5) in a volume of 50 mL/kg LRS.
www.moleculartherapy.org
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For the VLP procedure, an intravenous catheter was placed into the
distal peripheral saphenous vein of the right pelvic limb. The limb
was elevated and wrapped tightly from distal to proximal (from just
above catheter to mid-thigh) to massage as much blood as possible
from the limb. A tourniquet was then placed around the level of
the proximal thigh and tightened to prevent vascular ﬂow into and
out of the limb. The tourniquet extended from proximal tomid-thigh.
The limb was then lowered and unwrapped. The vector (rAAV1-CB-
rhAATmyc or rAAV8-CB-rhAATmyc) in a volume of 50 mL/kg was
infused over about 5–10 min. The tourniquet remained tight for
15 min following the infusion and was then released. The catheter
was removed, and the animal was allowed to recover from anesthesia
and returned to its home cage.
Physiological Parameter Monitoring During Infusions
Heart rate, respiratory rate, and body temperature were monitored
and documented during the surgical procedure to evaluate the status
of animals.
Post-Vector Administration Monitoring and Observations
After vector administration on the dosing day, animals subjected
to infusion procedures (groups 2–5) were observed for evidence of
erythema and edema of the infused site; blood vessel rupture;
compartment syndrome; traumatic rhabdomyolysis; high intravas-
cular pressure; bleeding (hematoma); pain; abnormal gait limping;
and potential damage to nerves, muscles, or the vascular network.
In addition, after vector administration, all animals (groups 1–5) were
monitored for clinical signs twice daily for 7 days. Behavioral and
clinical observations were made on awake animals, with special atten-
tion paid to the legs and any abnormal motor movements (including
posture or gait abnormalities).
For serum chemistry analyses, blood was collected into a serum sepa-
rator or clot tubes for centrifugation to separate cellular and serum
fractions. Serum chemistry was determined using a Hitachi Modular
Analytics Clinical Chemistry System (Roche Diagnostics, Indianapo-
lis, IN, USA).
Quantification of rhAAT-c-myc by Semi-Quantitative
Immunoblot of Serum
Serum samples and standard were diluted in 1:50 PBS. We mixed
10 mL diluted serum with 10 mL Tris-glycine SDS sample buffer
(2 Novex) and heated at 85C for 10 min. 20 mL treated sample
was run on Novex 12% Tris-glycine gels (Invitrogen, Carlsbad, CA,
USA) using Tris-glycine SDS running buffer (Invitrogen, Carlsbad,
CA, USA). The protein was then transferred to nitrocellulose mem-
branes using an i-Blot transfer device (Invitrogen, Carlsbad, CA,
USA). Membranes were blocked for 1 h at room temperature with
Odyssey Blocking Buffer (LI-COR Biosciences, Lincoln, NE, USA)
before being probed overnight with primary antibodies (1:1,000 dilu-
tion) (goat c-myc antibody; GeneTex catalog no. 30518). Infrared dye
(IR)-labeled secondary antibodies (1:5,000 dilution) were then
applied using IRDye 680LT Donkey Anti-Goat IgG (H + L). Blots
were visualized using the Odyssey Infrared imaging system (LI-
COR Biosciences, Lincoln, NE, USA), and images were processed
using an image studio program. All antibodies were used at the manu-
facturer-recommended dilutions.
Real-Time qRT-PCR
Frozen day-60 liver and gastrocnemius muscle samples (from dosed
limbs) were used to extract RNA using TRIzol Reagent according
to the manufacturer’s instructions (Thermo Fisher Scientiﬁc,
#15596026). The RNA was then treated with the TURBO DNA-free
Kit (Thermo Fisher Scientiﬁc, #AM1907) to remove DNA contami-
nation. A high-capacity RNA-to-cDNA kit (Thermo Fisher Scientiﬁc,
#4387406) was used for reverse transcription to obtain cDNAs. qPCR
was run using custom-designed Fam-labeled primers and probes tar-
geting the transgene-c-myc junction (Thermo Fisher Scientiﬁc,
#4448484). GAPDH was used as an endogenous control utilizing a
VIC primer-limited expression assay (Thermo Fisher Scientiﬁc,
#4451933).
gDNA Extraction and Real-Time PCR
AAV genome copies were measured using qPCR. The tissues were
harvested in a manner that prevented cross-contamination, snap
frozen in liquid nitrogen, and stored at 80C until gDNA was ex-
tracted. gDNA was isolated from the liver, right calf, left calf, right
quadriceps, left quadriceps, right inguinal lymph node, left
inguinal lymph node, cervical spinal cord, and lumbar spinal
cord using a DNeasy Blood & Tissue kit (QIAGEN, Valencia,
CA, USA) according to the manufacturer’s instructions. gDNA
concentrations were determined using the NanoDrop system
(Thermo Fisher Scientiﬁc, Waltham, MA, USA). AAV genome
copies present in gDNA were quantiﬁed by real-time PCR using
the QuantStudio 3 Real-Time PCR System (Thermo Fisher Scien-
tiﬁc, Waltham, MA, USA) according to the manufacturer’s instruc-
tions, and results were analyzed using the QuantStudio Design &
Analysis v1.4.1 software. Brieﬂy, primers and probes were designed
to the polyomavirus simian virus 40 polyadenylation sequence
(SV40) poly(A) region of the AAV vector used. A standard curve
was performed using plasmid DNA containing the same SV40pA
target sequence. PCR reactions contained a total volume of
50 mL and were run at the following conditions: 50C for 2 min,
95C for 10 min, and 45 cycles of 95C for 15 s and 60C for
1 min. DNA samples were assayed in triplicate. In order to assess
PCR inhibition, the third replicate was spiked with plasmid DNA
at a ratio of 100 copies per microgram of gDNA. If this replicate
was greater than 40 copies per microgram of gDNA, then the re-
sults were considered acceptable. If a sample contained 100 copies
or more per microgram of gDNA, it was considered positive for
vgs. If a sample contained less than 100 copies per microgram of
gDNA, it was considered negative for vgs. Vector copy numbers
reported are standardized per microgram of gDNA. Assay controls
include: a no template control (NTC) with acceptability criteria
of <15 copies and an established study-speciﬁc standard curve
slope range (±3 SD from three individual standard preparations
and runs).
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IFNg-ELISpot Response to AAV1 and AAV8 Capsids
PBMCs were isolated before dosing and at day 60 post-injection and
stimulated in vitro in R10 media supplemented with human inter-
leukin (IL)-2 and IL-7 (1 ng/mL) and a complete set of AAV1 or
AAV8 peptides (0.5 mg/mL) for 3 days. Then, cells were washed
and resuspended in R10 media supplemented with human IL-2 and
IL-7 (1 ng/mL) for 3 additional days. On day 6, cells were washed
and left to rest overnight in R10 media. On day 7, the IFNg-ELISpot
assay was performed according to the manufacturer’s recommenda-
tions (Monkey IFNg ELISpotBASIC, MABTech). PBMCs were stimu-
lated in vitro with overlapping peptides spanning the AAV1 or AAV8
capsid VP1 sequences and divided into 3 pools (15-mers overlapping
by 10 aa). A negative control consisted of unstimulated cells (medium
only), whereas CD3 and CD28 stimulation was used as a positive con-
trol for cytokine secretion.
Statistical Analysis
Serum AAT (Western Data) was analyzed using a non-parametric
one-way ANOVA (Kruskal-Wallis) on days 14 and 21 with a Dunn’s
multiple comparisons test. We could not analyze day-60 results due to
missing samples in the AAV8 groups. Signiﬁcance was set at p #
0.05. ELISpot data were analyzed using a DFR(2) test.
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